The doctor may also determine if you are actually experiencing a form of sexual dysfunction known as Hypoactive Sexual Desire Disorder (HSDD). Vyleesi, on the other hand, has a mechanism of action that is not so clear, but it ultimately aims to improve sexual desire. It involves the activation of melanocortin hormone receptors involved in sexual desire. The FDA notes clearly that the drug “Vyleesi does not enhance sexual performance”. Women who haven’t experienced menopause yet with a diagnosis of acquired hypoactive sexual desire disorder may be potential candidates to take the drug.

Source: The Guardian June 27, 2019 09:11 UTC